Temasek Holdings Private Ltd Grows Stock Position in Boston Scientific Corporation $BSX

Temasek Holdings Private Ltd lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 24.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,081,626 shares of the medical equipment provider’s stock after purchasing an additional 402,300 shares during the period. Boston Scientific comprises about 0.6% of Temasek Holdings Private Ltd’s holdings, making the stock its 29th largest holding. Temasek Holdings Private Ltd’s holdings in Boston Scientific were worth $198,483,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. FWL Investment Management LLC purchased a new stake in Boston Scientific during the 2nd quarter worth about $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific during the 4th quarter worth about $26,000. Colonial Trust Co SC lifted its holdings in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares during the last quarter. Bangor Savings Bank lifted its holdings in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund purchased a new stake in Boston Scientific during the 4th quarter worth about $29,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 0.5%

BSX opened at $46.69 on Tuesday. The stock has a market capitalization of $69.39 billion, a P/E ratio of 19.53, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. Boston Scientific Corporation has a one year low of $45.99 and a one year high of $109.50. The business’s 50-day simple moving average is $56.05 and its 200-day simple moving average is $74.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period last year, the firm earned $0.75 EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts anticipate that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

A number of analysts have issued reports on BSX shares. Leerink Partners decreased their price target on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, May 28th. Oppenheimer set a $90.00 price target on Boston Scientific in a report on Thursday, April 23rd. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Canaccord Genuity Group cut their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, Robert W. Baird set a $70.00 target price on Boston Scientific in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $85.08.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 9,800 shares of company stock worth $554,012 in the last three months. Insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.